Bill Text: MA S1025 | 2009-2010 | 186th General Court | Introduced
Bill Title: Further regulate appeals under the Group Insurance Commission
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2009-01-20 - Public Hearing date 6/22 at 11:00 AM in Hearing Room A1 [S1025 Detail]
Download: Massachusetts-2009-S1025-Introduced.html
The Commonwealth of Massachusetts
_______________
PRESENTED BY:
Scott P. Brown
_______________
To the
Honorable Senate and House of Representatives of the Commonwealth of
Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:
An Act further regulating appeals under the Group Insurance Commission
_______________
PETITION OF:
|
Name: |
District/Address: |
|
Scott P. Brown |
Norfolk, Bristol and Middlesex |
|
Mr. Hedlund |
Plymouth and Norfolk |
|
Mr. Knapik |
Second Hampden and Hampshire |
|
Mr. Tarr |
First Essex and Middlesex |
|
Mr. Tisei |
Middlesex and Essex |
|
Todd M. Smola |
1st Hampden |
|
Christine E. Canavan |
10th Plymouth |
[SIMILAR MATTER FILED IN PREVIOUS
SESSION
SEE SENATE, NO. S01461 OF .]
The Commonwealth of
Massachusetts
_______________
In the Year Two Thousand and Nine
_______________
An Act further regulating appeals under the Group Insurance
Commission.
Be
it enacted by the Senate and House of Representatives in General Court
assembled, and by the authority of the same, as follows:
SECTION 1. Chapter 32A of the General Laws is hereby by amended inserting the following section:-
Section 17J. Any person, who is dispensed a non-formulary or non-preferred brand name prescription drug, as determined under a pharmaceutical drug program established by the commission or through a pharmacy benefit manager contracted by the commission, may appeal that determination to the commission; and upon the submission of a statement by the person’s physician that, due to a medical necessity, only the non-formulary, or non-preferred brand name prescription drug can be dispensed, the person shall pay for the drug at the same rate required for the formulary or preferred brand name prescription drugs under such pharmaceutical drug program.
